Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval, Atorvastatin patent filing
Mumbai: Supriya Lifescience Ltd. has acquired approval from Brazil's health authority, ANVISA (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride This approval will help the company to grow its product range in Brazil and the rest of LATAM.
Supriya Lifescience Ltd. achieved two significant milestones, strengthening its position in international markets. It is the first firm in Brazil to have received regulatory permission for this highly specialised pharmaceutical, the Company claimed.
Esketamine hydrochloride is a vital drug to be used for treating mental illness.
"This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing. Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility," the Company stated in a release.
Dr. Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd. stated, "Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil."
